isradipine, (s)-isomer has been researched along with losartan in 1 studies
Studies (isradipine, (s)-isomer) | Trials (isradipine, (s)-isomer) | Recent Studies (post-2010) (isradipine, (s)-isomer) | Studies (losartan) | Trials (losartan) | Recent Studies (post-2010) (losartan) |
---|---|---|---|---|---|
6 | 0 | 1 | 7,231 | 1,245 | 2,118 |
Protein | Taxonomy | isradipine, (s)-isomer (IC50) | losartan (IC50) |
---|---|---|---|
Bile salt export pump | Homo sapiens (human) | 9.01 | |
Cytochrome P450 2C9 | Homo sapiens (human) | 2.882 | |
Angiotensin-converting enzyme | Homo sapiens (human) | 0.019 | |
Atrial natriuretic peptide receptor 3 | Homo sapiens (human) | 0.0018 | |
5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 0.019 | |
Type-1A angiotensin II receptor | Rattus norvegicus (Norway rat) | 0.0247 | |
Type-1B angiotensin II receptor | Rattus norvegicus (Norway rat) | 0.0234 | |
Adenosine receptor A2a | Rattus norvegicus (Norway rat) | 0.0032 | |
Type-1 angiotensin II receptor | Homo sapiens (human) | 0.047 | |
Type-1 angiotensin II receptor | Oryctolagus cuniculus (rabbit) | 0.025 | |
Type-2 angiotensin II receptor | Rattus norvegicus (Norway rat) | 0.0118 | |
Type-2 angiotensin II receptor | Homo sapiens (human) | 0.019 | |
Platelet glycoprotein VI | Homo sapiens (human) | 4 | |
Solute carrier organic anion transporter family member 1B3 | Homo sapiens (human) | 1.1481 | |
Type-1 angiotensin II receptor | Cavia porcellus (domestic guinea pig) | 0.018 | |
Solute carrier organic anion transporter family member 1B1 | Homo sapiens (human) | 0.2884 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
1 other study(ies) available for isradipine, (s)-isomer and losartan
Article | Year |
---|---|
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |